Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00293930 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis
A Phase 3 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 645
- Enrollment target
NCT00293930: Completed Phase 3 study, sponsored by Astellas Pharma.
NCT00293930 is a Phase 3 study that has completed, run by Astellas Pharma. The registered enrollment target is 645 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (16% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00293930, a Phase 3 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 645 participants
- Enrollment target
Study Summary
A study to assess the safety and effectiveness of tacrolimus cream in the treatment of psoriasis
Interventions
- DRUG Tacrolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 645 participants |
| Est. Completion | 2006-11 |
| Phase | Phase 3 |
What the finished NCT00293930 record still lists
NCT00293930 is an interventional study that assigns participants to a tested intervention. The registered 645 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (16% lower).
The record links to 0 conditions, and to 1 intervention - of which Tacrolimus is the first listed.
NCT00293930 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00293930 about?
NCT00293930 is a clinical study titled "A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis". A study to assess the safety and effectiveness of tacrolimus cream in the treatment of psoriasis
What is the current status of trial NCT00293930?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 645 participants. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00293930?
The interventions under investigation include: Tacrolimus (DRUG).
Who is sponsoring clinical trial NCT00293930?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00293930's enrollment target sits among peer trials
645 572nd of 2000 higher than 1,429 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07012395 · 645 participants · Phase 2
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
- NCT04863222 · 646 participants · Phase 4
Clinical and Radiographic Success of MTA vs Biodentine
- NCT05146297 · 644 participants · NA
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
- NCT06994442 · 644 participants · Phase 3
Optimizing Pain Treatment in Children On Mechanical Ventilation